MacroGenics Inc. (NASDAQ:MGNX)’s share price was down 3.7% on Tuesday . The stock traded as low as $27.24 and last traded at $27.38, with a volume of 79,057 shares changing hands. The stock had previously closed at $28.43.

Several equities analysts have recently weighed in on MGNX shares. Morgan Stanley restated a “hold” rating on shares of MacroGenics in a research report on Thursday, June 30th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of MacroGenics in a research report on Tuesday, June 14th. Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a research report on Wednesday. BTIG Research started coverage on MacroGenics in a research report on Thursday, April 7th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Leerink Swann restated an “outperform” rating and issued a $47.00 target price on shares of MacroGenics in a research report on Thursday, May 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. MacroGenics currently has an average rating of “Buy” and a consensus target price of $40.25.

The firm’s market capitalization is $1.01 billion. The stock has a 50 day moving average of $26.34 and a 200-day moving average of $21.42.

MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.21. Equities analysts expect that MacroGenics Inc. will post ($2.29) EPS for the current year.

In other MacroGenics news, CMO Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $27.22, for a total transaction of $136,100.00. Following the transaction, the chief marketing officer now owns 5,000 shares in the company, valued at approximately $136,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Lynn Cilinski sold 8,922 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $27.22, for a total value of $242,856.84. Following the transaction, the vice president now owns 10,845 shares in the company, valued at approximately $295,200.90. The disclosure for this sale can be found here.

Several large investors have recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its stake in MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock worth $8,282,000 after buying an additional 909 shares in the last quarter. Marshall Wace LLP boosted its stake in MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock worth $2,902,000 after buying an additional 45,422 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 20,929 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in MacroGenics by 46.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 716,350 shares of the biopharmaceutical company’s stock worth $22,185,000 after buying an additional 227,260 shares in the last quarter. Finally, GAM Holding AG boosted its stake in MacroGenics by 118.3% in the fourth quarter. GAM Holding AG now owns 63,100 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 34,200 shares in the last quarter.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.